(crizotinib)

Medication Guide

Download Consumer Medicine Information

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Prescribing Information

Download Prescribing Information

Health Professional Information

What is XALKORI?

What is XALKORI?

•
adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1.
•
children 1 year of age and older and young adults with ALCL when your ALCL with a defect in a gene called ALK has returned or you have tried a treatment and it did not work or is no longer working.
o
It is not known if XALKORI is safe and effective in older adults with ALCL.
•
adults and children 1 year of age and older with IMT when your IMT with a defect in a gene called ALK cannot be removed by surgery, has returned, or you have tried a treatment and it did not work or is no longer working.

It is not known if XALKORI is safe and effective in children younger than 1 year of age with ALCL or IMT, or in any children with NSCLC.

Before taking XALKORI, tell your healthcare provider about all of your medical conditions, including if you:

•
have liver or kidney problems
•
have lung problems
•
have heart problems, including a condition called long QT syndrome
•
have vision or eye problems
•
are pregnant or plan to become pregnant. XALKORI can harm your unborn baby.
Females who are able to become pregnant:
o
Your healthcare provider will check to see if you are pregnant before starting treatment with XALKORI.
o
Effective birth control (contraception) should be used during treatment with XALKORI and for 45 days after the last dose of XALKORI.
o
Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with XALKORI.
 
Males who have female partners who can become pregnant:
o
You should use condoms during treatment with XALKORI and for 90 days after the last dose of XALKORI.
•
are breastfeeding or plan to breastfeed. It is not known if XALKORI passes into your breast milk. Do not breastfeed during treatment with XALKORI and for 45 days after the last dose. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. XALKORI can affect the way other medicines work, and other medicines can affect how XALKORI works.

Additional Resources

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine or vaccine.

Speak with a Pfizer Medical Information Professional regarding your Pfizer medicine or vaccine inquiry.

Available 9AM-5PM ET Monday to Friday; excluding holidays.

 

Submit a medical question for a Pfizer medicine or a vaccine. 

The submission will be reviewed during our standard business hours.

To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this medication, click the link below to submit your information: 
Pfizer Safety Reporting Site

*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.

If you cannot use the above website to report an adverse event related to a Pfizer medication, please call (800) 438-1985.

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or by calling (800) 332-1088.